Press Releases

Press Releases

July 16, 2019
Akcea and Ambry Genetics grow partnership, providing easily accessible, no-cost, confidential genetic testing and genetic counseling services to people with suspected hereditary ATTR amyloidosis BOSTON and Aliso Viejo, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
June 26, 2019
Multiple clinical presentations focus on the long-term clinical benefits of treatment with TEGSEDI® (inotersen) BOSTON and CARLSBAD, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc.
June 20, 2019
Multiple clinical presentations focus on the long-term clinical benefits of treatment with TEGSEDI® (inotersen) BOSTON and CARLSBAD, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc.
May 28, 2019
BOSTON , May 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that management will present a company overview at the
May 8, 2019
Achieved First Quarter 2019 TEGSEDI ® (inotersen) Global Net Product Revenues of $7 Million   Novartis exercised its option to license AKCEA-APO(a)-L Rx Received marketing authorization for WAYLIVRA ® (volanesorsen) in E.U. Conference Call Webcast Wednesday, May 8 , 4:30 p.m.
May 7, 2019
NEURO-TTR phase 3 open-label extension study showed TEGSEDI ® ( inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy Ionis Logo Greater efficacy and clinical benefit observed with early initiation of TEGSEDI and no
May 7, 2019
WAYLIVRA is the only therapy for Familial Chylomicronemia Syndrome, or FCS, a devastating, ultra-rare disease BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
May 2, 2019
Multiple clinical presentations at AAN focus on the long-term clinical benefits of treatment with TEGSEDI™   (inotersen) An oral presentation of long-term efficacy and safety with 2-year data from the NEURO-TTR open-label study to be presented by Dr. Tom Brannagan BOSTON , May 02, 2019 (GLOBE
April 24, 2019
Webcast scheduled for Wednesday, May 8th at 4:30 p.m. Eastern Time BOSTON , April 24, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Wednesday, May 8 th at 4:30 p.m.
March 15, 2019
Presentations focus on the benefits of treatment with TEGSEDI™ (inotersen) and results show continued efficacy with long-term exposure in the NEURO-TTR open-label extension study BOSTON and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.